Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has signed a collaboration and license agreement with AffyXell Therapeutics (“AffyXell”), the recently established joint venture with Daewoong Pharmaceutical (“Daewoong”), to develop Affimer proteins to be used by AffyXell for the generation of new cell and gene therapies.
Intelligent Ultrasound Group plc (AIM: MED), the artificial intelligence (AI) based ultrasound software and simulation company, announces that it has signed its first long-term licence and co-development agreement for its AI software with one of the world’s leading ultrasound equipment manufacturers.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular diseaseand diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has signed a non-exclusive license agreement with Tenshindo, Co. Ltd. for the use of Lactobacillus plantarum LPLDL® (“LPLDL®”) in cardiovascular food supplements in Japan.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular diseaseand diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has signed a license agreement with Kappa Bioscience AS for the use of Lactobacillus plantarum LPLDL® in a new application area within cardiovascular health.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular diseaseand diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has signed a license agreement with Nutrilinea Srl. for the use of LPLDL® in a food supplement for the reduction of high blood pressure.